GPX4 and cancer: Targeting DHODH can therefore selectively eliminate cancer cells that are otherwise refractory to apoptosis or necroptosis, while sparing normal cells that rely more heavily on salvage pathways and cytosolic GPX4 for redox protection [17,51].